Arbutus Biopharma Corp ( ABUS) - Key Metrics
ABUS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.01 | -$0.03 | -$0.03 | -$0.03 |
| 2026Q1 | $0.92 | $0.88 | -$0.04 | -$0.04 |
| 2025Q4 | $0.01 | -$0.02 | -$0.02 | -$0.02 |
| 2025Q3 | $0 | -$0.04 | -$0.03 | -$0.03 |
| 2025Q2 | $0.06 | $0.01 | -$0.08 | -$0.08 |
ABUS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -40 |
| 2026Q1 | 0% | 1.28 |
| 2025Q4 | 0% | -61.67 |
| 2025Q3 | 0% | -28.38 |
| 2025Q2 | 0% | 58.52 |
ABUS
Price: $4.86
52 week price:
Payout Ratio Range:
Earnings Per Share: 0.79 USD
P/E Ratio: 5.91
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 545700
Ebitda: -10.9 millionMarket Capitalization: 1.0 billion